Skip to main content
SpringerLink
Log in
Book cover

The Sedated Society pp 123–161Cite as

Palgrave Macmillan

Neuroleptic (Antipsychotic) Drugs: An Epidemic of Tardive Dyskinesia and Related Brain Injuries Afflicting Tens of Millions

  • Chapter
  • First Online:

Abstract

Neuroleptic (antipsychotic) drugs affect the individual more like a viral brain disease called lethargic encephalitis than like any medical treatment. The neuroleptic pioneers saw how these drugs caused emotional indifference, disinterest, and apathy similar to lethargic encephalitis. They realized the drugs also produced neurological syndromes similar to those associated with the epidemic encephalitis, including Parkinsonism and tardive dyskinesia (TD). They predicted the new drugs could cause an epidemic of brain injury similar to the viral encephalitis. Given the severe adverse reactions TD can produce, even if the drugs brought enormous benefit, the cost would be too high. Yet the drugs have no curative value whatsoever and can only work by imposing encephalitis-like lethargy, disinterest, and apathy upon individuals, making them seemingly less troublesome to themselves and others. It is time to reconsider their use.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Abboud, L. (2005, May 25). Treating children for bipolar disorder? Doctors try powerful drugs on kids as young as age 4 (p. D1). Wall Street Journal.

    Google Scholar 

  • Abilify Full Prescribing Information (the label) and Medication Guide. (2016, January). Retrieved on May 30, 2016, from Abilify homepage https://www.otsuka-us.com/media/images/AbilifyPI_538.pdf

  • Abrahamson, I. (1935). Lethargic Encephalitis. New York: Privately published.

    Google Scholar 

  • Abrahamson, J. (2005). Overdosed America: How the pharmaceutical companies are corrupting science, misleading doctors, and threatening your health. New York: Harper Perennial.

    Google Scholar 

  • Addonizio, G., Susman, V. L., & Roth, S. D. (1986). Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. The American Journal of Psychiatry, 143(12), 1587–1590. doi:10.1176/ajp.143.12.1587.

    Article  PubMed  Google Scholar 

  • American Geriatrics Society. (2012a). Updated beers criteria for potentially inappropriate medication use in older adults by the American Geriatrics Society 2012 beers criteria update expert panel. Journal of American Geriatrics Society, 60(4), 616–631.

    Article  Google Scholar 

  • American Geriatrics Society. (2012b). Identifying medications that older adults should avoid or use with caution: The 2012 American Geriatrics Society Updated Beers Criteria. The American Geriatrics Society Foundation for Health in Aging.

    Google Scholar 

  • American Psychiatric Association. (1980). Tardive dyskinesia: Task force report. Washington, DC: Author.

    Google Scholar 

  • American Psychiatric Association Task Force on Tardive Dyskinesia. (1985, July). Letter to APA membership with attachment, tardive dyskinesia. Washington, DC: Author.

    Google Scholar 

  • American Psychiatric Association. (1992). Tardive dyskinesia: A task force report of the American psychiatric association. Washington, DC: Author.

    Google Scholar 

  • American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders, four edition, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.

    Book  Google Scholar 

  • American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders, fifth edition (DSM-V). Washington, DC: American Psychiatric Association.

    Book  Google Scholar 

  • Angell, M. (2002). The truth about drug companies: How they deceive us and what to do about it (p. 2002). New York: Harper Random House.

    Google Scholar 

  • Applbaum, K. (2009). Getting to yes: Corporate power and the creation of a psychopharmaceutical blockbuster. Culture, Medicine and Psychiatry, 33(2), 185–215. doi:10.1007/s11013-009-9129-3.

    Article  PubMed  Google Scholar 

  • Asnis, G. M., Leopold, M. A., Duvoisin, R. C., & Schwartz, A. H. (1977). A survey of tardive dyskinesia in outpatients. American Journal of Psychiatry, 134, 1367–1330.

    Article  PubMed  Google Scholar 

  • Association for Research in Nervous and Mental Disease. (1921). Acute Epidemic Encephalitis (Lethargic Encephalitis). New York: Paul B. Hoeber (Bibliolife Reproduction Series).

    Google Scholar 

  • Attorney General of the State of Texas. (2012, January). Texas Attorney General Secures $158 Million Agreement With Drug Maker [Johnson & Johnson for Risperdal] Over Medicaid Fraud Allegations. Retrieved on March 15, 2016, from https://texasattorneygeneral.gov/oagnews/release.php?id=3956

  • Breggin, P. (1979). Electroshock: Its brain-disabling effects. New York: Springer.

    Google Scholar 

  • Breggin, P. (1981). Psychosurgery as brain-disabling therapy. In M. Dongier & E. Wittkower (Eds.), Divergent views in psychiatry (pp. 302–326). Hagerstown, Maryland: Harper & Row.

    Google Scholar 

  • Breggin, P. (1983). Psychiatric drugs: Hazards to the brain. New York: Springer Publishing Company.

    Google Scholar 

  • Breggin, P. (1990). Brain damage, dementia and persistent cognitive dysfunction associated with neuroleptic drugs. Journal of Mind and Behavior, 11, 425–463.

    Google Scholar 

  • Breggin, P. (1993). Parallels between neuroleptic effects and lethargic encephalitis: The production of dyskinesia and cognitive disorders. Brain and Cognition, 23, 8–28. doi:10.1006/brcg.1993.1041.

    Article  PubMed  Google Scholar 

  • Breggin, P. (1991). Toxic psychiatry. New York: St. Martin’s Press.

    Google Scholar 

  • Breggin, P. (1997). brain disabling treatments in psychiatry: Drugs, electroshock and the role of the FDA. New York: Springer Publishing Company.

    Google Scholar 

  • Breggin, P. (1998). Analysis of adverse behavioral effects of benzodiazepines with a discussion of drawing scientific conclusions from the FDA’s Spontaneous Reporting System. Journal of Mind and Behavior, 19, 21–50.

    Google Scholar 

  • Breggin, P. (2007). Intoxication anosognosia: The spellbinding effect of psychiatric drugs. International Journal of Risk and Safety and Medicine, 19, 3–15.

    Google Scholar 

  • Breggin, P. (2008a). Brain-disabling treatments in psychiatry, second edition: Drugs, electroshock and the psychopharmaceutical complex. New York: Springer Publishing Company.

    Google Scholar 

  • Breggin, P. (2008b). Medication madness: The role of psychiatric drugs in cases of violence, suicide and crime. New York: St. Martin’s Press.

    Google Scholar 

  • Breggin, P. (2011). Psychiatric drug-induced chronic brain impairment (CBI): Implications for long-term treatment with psychiatric medication. International Journal of Risk & Safety in Medicine, 23(4), 193–200.

    Google Scholar 

  • Breggin, P. (2013). Psychiatric drug withdrawal: A guide for prescriber, patients, therapists and their families. New York: Springer Pub Company.

    Google Scholar 

  • Breggin, P. (2014). The rights of children and parents in regard to children receiving psychiatric drugs. Children & Society, 28, 231–241.

    Article  Google Scholar 

  • Breggin, P. (2016). Rational principles of psychopharmacology for therapists, healthcare providers and clients. Journal of Contemporary Psychotherapy, 46(1–13), 2016.

    Google Scholar 

  • Breggin, P., & Stern, E. (Eds.). (1996). Psychosocial approaches to deeply disturbed persons. New York, NY: Haworth Press.

    Google Scholar 

  • Brill, H. (1959). Postencephalitic states or condition s. In S. Arieti (Ed.), American handbook of psychiatry (Vol. II, pp. 1163–1174). New York: Basic Books.

    Google Scholar 

  • Brown, P., & Funk, S. C. (1986). Tardive dyskinesia: Barriers to the professional recognition of an iatrogenic disease. Journal of Health and Social Behavior, 27, 116–132.

    Article  PubMed  Google Scholar 

  • Brunton, L. (Ed.). (2011). Goodman and Gilman’s the pharmacological basis of therapeutics (12th ed.). New York: McGraw Hill Medical.

    Google Scholar 

  • Burke, R. E. (1992). Neuromuscular effects of neuroleptics: Dystonia. In J. Kane & J. Lieberman (Eds.), Adverse effects of psychotropic drugs. New York: Guilford Press.

    Google Scholar 

  • Burke, R. E., Fahn, S., Jankovic, J., et al. (1982). Tardive dystonia: Late onset and persistent dystonia caused by antipsychotic drugs. Neurology, 32, 1334–1346.

    Google Scholar 

  • Caroff, S., Hurford, I., Lybrand, J., & Campbell, C. (2011). Movement disorders induced by antipsychotic drugs: Implications of the CATIE schizophrenia trial. Neurol Clin, 29(2011), 127–148.

    Article  PubMed  PubMed Central  Google Scholar 

  • Chouinard, G., Annable, I., Mercier, P., & Ross-Chouinard, A. (1988). A 5-year prospective longitudinal study of tardive dyskinesia. Journal of Clinical Psychopharmacology, 8(4), 21S–26S.

    PubMed  Google Scholar 

  • Cohen, D., & McCubbin, M. (1990). The political economy of tardive dyskinesia: Asymmetries in power and responsibility. Journal of Mind and Behavior, 11, 465–488.

    Google Scholar 

  • Cozza, S., Crawford, G., & Duncan, M. (2003). Treatment of children and adolescents, Chapter 23. InTextbook of clinical psychiatry (4th ed., pp. 1399–1145). Washington, DC: American Psychiatric Publishing.

    Google Scholar 

  • Davies, J. (2013). Cracked: The unhappy truth about psychiatry. New York: Pegasus.

    Google Scholar 

  • Decker, H. (2013). The making of DSM-III: A diagnostic manual’s conquest of American psychiatry (p. 2013). New York: Oxford University Press.

    Google Scholar 

  • de Girolamo, G. (1996). WHO studies in schizophrenia: An overview of the results and their implications for the understanding of the disorder. In P. Breggin & E. Stern (Eds.), Psychosocial approaches to deeply disturbed persons (pp. 213–231). New York, NY: Haworth Press.

    Google Scholar 

  • Deniker, P. (1970). Introduction of neuroleptic chemotherapy into psychiatry. In F. Ayd Jr. & B. Blackwell (Eds.), Discoveries in biological psychiatry (pp. 155–164). Philadelphia: J. B. Lippincott.

    Google Scholar 

  • Department of Justice (DOJ) of the United States. (2013). Johnson & Johnson to pay more than $2.2 billion to resolve criminal and civil investigations: Allegations include off-label marketing and kickbacks to doctors and pharmacists, November 4, 2013. Washington, DC, U.S. Retrieved March 30, 2015, from https://www.justice.gov/opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-investigations

  • Dorph-Petersen, K.-A., Pierri, J., Perel, J., Sun, Z., Sampson, A., & Lewis, D. (2005). The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: A comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology, 30, 1649–1661. doi:10.1038/sj.npp.1300710.

    Article  PubMed  Google Scholar 

  • Dwyer, D., Lu, X.-H., & Bradley, J. (2003). Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Research, 971, 31–39.

    Article  PubMed  Google Scholar 

  • Food and Drug Administration (FDA). (2016, May 3). Aripiprazole (Abilify, Abilify Maintena, Aristada): Drug safety communication—FDA warns about new impulse-control problems. MedWatch: The FDA Safety Information and Adverse Event Reporting Program . Retrieved May 31, 2016, from http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm498823.htm

  • Fusar-Polia, P., Smieskovab, R., Kemptona, M., Hoc, B., Andreasen, N., & Borgwardt, S. (2013). Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neuroscience & Biobehavioral Reviews 37, 1680-1681. Retrieved May 29, 2016, from http://www.sciencedirect.com/science/article/pii/S0149763413001486

  • Ganzini, L., Casey, D., Hoffman, W., & McCall, A. (1993). The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Archives of Internal Medicine, 153, 1469–1475.

    Article  PubMed  Google Scholar 

  • Glenmullen, J. (2000). Prozac Backlash. New York: Simon and Schuster.

    Google Scholar 

  • Goldberg, E. (1985). Akinesia, tardive dysmentia, and frontal lobe disorder in schizophrenia. Schizophrenia Bulletin, 11, 255–263.

    Article  PubMed  Google Scholar 

  • Gøtzsche, P. C. (2016). Deadly psychiatry and organized denial. Copenhagen, Denmark: People’s Press.

    Google Scholar 

  • Greenberg, D. (2007). Neurogenesis and stroke. CNS & Neurological Disorders—Drug Targets, 6, 321–325.

    Article  Google Scholar 

  • Gualtieri, C., & Barnhill, L. (1988). Tardive dyskinesia in special populations. In M. E. Wolf & A. D. Mosnaim (Eds.), Tardive dyskinesia: Biological mechanisms and clinical aspects (pp. 137–154). Washington, DC: American Psychiatric Press.

    Google Scholar 

  • Haag, H., Ruther, E., & Hippius, H. (1992). Tardive dyskinesia. Seattle: Hogrefe & Huber.

    Google Scholar 

  • Harrow, M., & Jobe, T. H. (2007). Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: A 15-year multifollow-up study. Journal of Nervous and Mental Diseases, 195(5), 406–414.

    Google Scholar 

  • Herskowitz, J. (1987). Developmental neurotoxicity. In C. Popper (Ed.), Psychiatric pharmacosciences of children and adolescents (pp. 81–123). Washington, DC: American Psychiatric Press.

    Google Scholar 

  • Ho, B. C., Andreasen, N. C., Ziebell, S., Pierson, R., & Magnotta, V. (2011). Long-term antipsychotic treatment and brain volumes: A longitudinal study of first-episode schizophrenia. Archives of General Psychiatry, 68(2), 128–137.

    Article  PubMed  PubMed Central  Google Scholar 

  • IMS Institute for Health Care Informatics. (2012). The use of medicines in the United States: Review of 2011. Retrieved May 28, 2016, from https://www.imshealth.com/files/web/IMSH%20Institute/Reports/The%20Use%20of%20Medicines%20in%20the%20United%20States%202011/IHII_Medicines_in_U.S_Report_2011.pdf

  • International Center for the Study of Psychiatry and Psychology (ICSPP).(2009). The conscience of psychiatry: The reform work of Peter R. Breggin, MD. Ithaca, NY: Lake Edge Press.

    Google Scholar 

  • Inuwa, I., Horobin, R., & Williams, A. (1994). A TEM study of white blood cells from patients under neuroleptic therapy. ICEM 13 Paris [International Congress of Electron Microscopy], pp. 1091–1092.

    Google Scholar 

  • Jeste, D. V., Wisniewski, A. A., & Wyatt, R. J. (1986). Neuroleptic-associated tardive syndromes. Psychiatric Clinics of North America, 9, 183–192.

    PubMed  Google Scholar 

  • Jeste, D. V., Lacro, J. P., Gilbert, P. L., Kline, J., & Kline, N. (1993). Treatment of late-life schizophrenia with neuroleptics. Schizophrenia Bulletin, 19, 817–830.

    Article  PubMed  Google Scholar 

  • Kapur, S., Zipursky, R., & Remington, G. (1999). Clinical and theoretical implications of 5-HT 2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. American Journal of Psychiatry, 156, 286–293.

    PubMed  Google Scholar 

  • Karon, B. (2005). Recurrent psychotic depression is treatable by psychoanalytic therapy without medication. Ethical Human Psychology and Psychiatry, 7, 45–56.

    Google Scholar 

  • Karon, B. (2003). The tragedy of schizophrenia without psychotherapy. Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry, 331, 89–118.

    Article  Google Scholar 

  • Karon, B. (1989). Psychotherapy versus medications for schizophrenia: Empirical comparisons. Chapter 4. In S. Fisher & R. Greenberg (Eds.), The limits of biological treatments for psychological distress (pp. 105–150). Hillsdale, New Jersey: Lawrence Erlbaum Associates.

    Google Scholar 

  • Kim, H., Yumkham, S., Choi, J., Kim, E.-K., Kim, Y., Ryu, S., & Suh, P.-G. (2006). Haloperidol induces calcium ion influx via L-type calcium channels in hippocampal HN33 cells and renders the neurons more susceptible to oxidative stress. Molecules and Cells, 22, 51–57.

    PubMed  Google Scholar 

  • Kirk, S., & Kutchins, H. (2003). Making us crazy. New York: Free Press.

    Google Scholar 

  • Kirsh, I. (2009). The emperor’s new drugs: Exploding the antidepressant myth. New York: Random House.

    Google Scholar 

  • Klawans, J. L. (1985). Recognition and diagnosis of tardive dyskinesia. Journal of Clinical Psychiatry, 46(4, Sec. 2), 3–7.

    PubMed  Google Scholar 

  • Konopaske, G. T., Dorph-Petersen, K. A., Pierri, J. N., Wu, Q., Sampson, A. R., & Lewis, D. A. (2007). Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology, 32(6), 1216–1223. doi:10.1038/sj.npp.1301233.

    Article  PubMed  Google Scholar 

  • Konopaske, G. T., Dorph-Petersen, K. A., Sweet, R. A., Pierri, J. N., Zhang, W., Sampson, A. R., et al. (2008). Effect of chronic psychotic exposure to astrocyte and oligodendrocytic numbers in macaque monkeys. Biological Psychiatry, 63(8), 759–765. doi:10.1016/j.biopsych.2007.08.018.

    Article  PubMed  Google Scholar 

  • Leisman, G., Braun-Benjamin, O., & Melillo, R. (2014). Cognitive-motor interactions of the basal ganglia in development. Frontiers in Systems Neuroscience, 8, 1–18.

    Article  Google Scholar 

  • Lieberman, J. A., & Stroup, T. S. (2011). The NIMH-CATIE schizophrenia study: What did we learn? The American Journal of Psychiatry, 168(8), 770–775. doi:10.1176/appi.ajp.2011.11010039.

    Article  PubMed  Google Scholar 

  • Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D., & Hsiao, J. (2005). For the clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine, 353(12), 1209–1223. doi:10.1056/NEJMoa051688.

    Article  PubMed  Google Scholar 

  • Light, D. (2010). The risks of prescription drugs. New York: Columbia University.

    Book  Google Scholar 

  • Matheson Commission, Third Report. (1939). Epidemic encephalitis. New York: Columbia University.

    Google Scholar 

  • Miller, D. D., Caroff, S. N., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., et al. (2008). Extrapyramidal side-effects of antipsychotics in a randomised trial. British Journal of Psychiatry, 193, 279–288. doi:10.1192/bjp.bp.108.050088.

    Article  PubMed  PubMed Central  Google Scholar 

  • Miller, L., & Jankovic, J. (1999). Drug-induced dyskinesias: An overview. In A. Joseph & R. Young (Eds.), Movement disorders in neurology and neuropsychiatry (2nd ed., pp. 2–30). Malden, Massachusetts: Blackwell Science.

    Google Scholar 

  • Moncrieff, J. (2007a). The myth of the chemical cure: A critique of psychiatric drug treatment. Palgrave Macmillan: Hampshire.

    Book  Google Scholar 

  • Moncrieff, J. (2007b). Understanding psychotropic drug action: The contribution of the brain-disabling theory. Ethical Human Psychology and Psychiatry, 9, 170–179.

    Article  Google Scholar 

  • Moncrieff, J. (2013). The bitterest pills: The troubling story of antipsychotic drugs. New York: Palgrave.

    Book  Google Scholar 

  • Mosher, L. (1996). Soteria: A therapeutic community for psychotic persons In P. R. Breggin & E. M. Stern (Eds.), Psychosocial approaches to deeply disturbed persons (pp. 43–58). New York, NY: Haworth Press.

    Google Scholar 

  • Moreno, C., Laje, G., Blanco, C., Jiang, H., Schmidt, A. B., & Olfson, M. (2007). National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Archives of General Psychiatry, 64(9), 1032–1039.

    Article  PubMed  Google Scholar 

  • Myslobodsky, M. (1993, September). Central determinants of attention and mood disorder in tardive dyskinesia (“tardive dysmentia”). Brain and Cognition, 23(1), 88–101.

    Article  PubMed  Google Scholar 

  • Myslobodsky, M. (1986). Anosognosia in tardive dyskinesia: “Tardive dysmentia” or “tardive dementia”? Schizophrenia Bulletin, 12, 1–6.

    Article  PubMed  Google Scholar 

  • Myslobodsky, M., Tomer, R., Holden, T., Kempler, S., & Sigol, M. (1985). Cognitive impairment in patients with tardive dyskinesia. Journal of Nervous and Mental Disease, 173, 156–160.

    Article  PubMed  Google Scholar 

  • Navari, S., & Dazzan, P. (2009). Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychological Medicine, 39(11), 1763–1777. doi:10.1017/S0033291709005315.

    Article  PubMed  Google Scholar 

  • Pachter, W., Fox, R., Zimbardo, P., & Antonuccio, D. (2007). Corporate funding and conflicts of interest: A primer for psychologists. American Psychologist, 62(9), 1005–1015. doi:10.1037/0003-066X.62.9.1005.

    Article  PubMed  Google Scholar 

  • Ramaekers, J. (1998). Behavioural toxicity of medicinal drugs practical consequences, incidence, management and avoidance. Drug Safety, 18(3), 189–208.

    Article  PubMed  Google Scholar 

  • Richardson, M. A., Craig, T., & Branchey, M. (1982). Intra-patient variability in the measurement of tardive dyskinesia. Psychopharmacology, 76, 269–272.

    Article  PubMed  Google Scholar 

  • Risperdal. (2014, April). FDA-approved Full Prescribing Information (the label). Retrieved Janssen homepage May 30, 2016, from http://www.janssen.com/us/sites/www_janssen_com_usa/files/products-documents/risperdal.pdf

  • Rosebush, P., & Mazurek, M. F. (1999). Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology, 52(4), 782–785.

    Article  PubMed  Google Scholar 

  • Sachdev, P. (1993). Clinical characteristics of 15 patients with tardive dystonia. American Journal of Psychiatry, 150, 498–500. doi:10.1176/ajp.150.3.498.

    Article  PubMed  Google Scholar 

  • Saltz, G. L., Woerner, M. G., Kane, J. M., Lieberman, J. A., Alvir, J. M. J., Bergmann, K. J., et al. (1991). Prospective study of tardive dyskinesia incidence in the elderly. Journal of the American Medical Association, 266, 2402–2406.

    Article  PubMed  Google Scholar 

  • Sarchet, P. (2011). Harvard scientists disciplined for not declaring ties to drug companies. Retrieved from http://blogs.nature.com/news/2011/07/Harvard_scientists_disciplined

  • Schatzberg, A., Cole, J., & DeBattista, C. (1997). Manual of clinical psychopharmacology (3rd ed.). Washington, DC: American Psychiatric Association.

    Google Scholar 

  • Seikkula, J. (2006). Five year experience of first-episode nonaffective psychosis in open-dialogue approach. Journal of Psychotherapy Research, 16, 214–228.

    Article  Google Scholar 

  • Seikkula, J., Alakare, B., Aaltonen, J., Holma, J., Rasinkangas, A., & Lehtinen, V. (2003). Open dialogue approach: Treatment principles and preliminary results of a two-year follow-up of first episode schizophrenia. Ethical Human Sciences and Services, 5(3), 163–182.

    Google Scholar 

  • Smith, J., Kucharski, M., Oswald, T., & Waterman, M. (1979). A systematic investigation of tardive dyskinesia inpatients. American Journal of Psychiatry, 136, 918–922. doi:10.1176/ajp.136.7.918.

    Article  PubMed  Google Scholar 

  • Smith, K., & Laboratories, F. (1964). Ten years experience with thorazine: 1954–1964. Philadelphia: Author.

    Google Scholar 

  • Southerland, M. R. (2005, June 9). Addendum to previous review: Further analysis of tardive dyskinesia cases [involving metoclopramide], (NDA 21-645), (DO5036). Rockville, Maryland: Safety Evaluator, Division of Drug Risk Evaluation, Food and Drug Administration.

    Google Scholar 

  • Teller, D., & Denber, H. (1970). Mescaline and phenothiazines: Recent studies on subcellular localization and effects upon membranes. In A. Lajtha (Ed.), Protein metabolism of the nervous system (pp. 685–698). New York: Plenum.

    Chapter  Google Scholar 

  • Van Haren, N., Schnack, H., Cahn, W., Heuvel, P., Lepage, C., Collins, L., et al. (2011). Changes in cortical thickness during the course of illness in schizophrenia. Archives of General Psychiatry, 68(9), 871–880. doi:10.1001/archgenpsychiatry.2011.88.

    Article  PubMed  Google Scholar 

  • Van Putten, T. (1974). Why do schizophrenic patients refuse to take their drugs? Archives of General Psychiatry, 31, 67–72.

    Article  PubMed  Google Scholar 

  • Van Putten, T. (1975). The many faces of akathisia. Comprehensive Psychiatry, 16, 43–46.

    Article  PubMed  Google Scholar 

  • Van Putten, T., May, P., & Marder, S. (1984). Akathisia with haloperidol and thiothixene. Psychopharmacology Bulletin, 20, 114–117.

    PubMed  Google Scholar 

  • Van Putten, T., & May, P. (1978). Akinetic depression in schizophrenia. Archives of General Psychiatry, 35, 1101–1107.

    Article  PubMed  Google Scholar 

  • Von Economo, C. (1931). Encephalitis lethargica: Its sequelae and treatment. London: Oxford University Press.

    Google Scholar 

  • Watters, E. (2011). Crazy like us: The globalization of the American psyche. New York: Free Press.

    Google Scholar 

  • Whitaker, R. (2010). Anatomy of an epidemic. New York: Crown.

    Google Scholar 

  • Whitaker, R., & Cosgrove, L. (2015). Psychiatry under the influence: Institutional corruption, social injury, and prescriptions for reform. New York: Palgrave Macmillan.

    Book  Google Scholar 

  • Wojcieszek, J. (1998). Drug-induced movement disorders. Chapter 12. In J. Biller (Ed.), Iatrogenic neurology (pp. 215–231). Boston: Butterworth-Heinemann.

    Google Scholar 

  • Wolf, M. E., & Brown, P. (1987). Overcoming institutional and community resistance to a tardive dyskinesia management program. Hospital and Community Psychiatry, 38, 65–68.

    PubMed  Google Scholar 

  • Woods, S., Morgenstern, H., Saksa, J., Walsh, B., Sullivan, M., Money, R., et al. (2010). Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: A prospective cohort study. Journal of Clinical Psychiatry, 71, 463–474. doi:10.4088/JCP.07m03890yel.

    Article  PubMed  PubMed Central  Google Scholar 

  • Worster-Drought, C., & Hardcastle, D. N. (1924–1925). A contribution to the psychopathology of residual encephalitis lethargica. Journal of Neurology and Psychopathology., 5, 146–150.

    Article  PubMed  PubMed Central  Google Scholar 

  • Yassa, R., Nastase, C., Camille, Y., & Belzile, L. (1988). Tardive dyskinesia in a psychogeriatric population. In M. E. Wolf & A. D. Mosnaim (Eds.), Tardive dyskinesia: Biological mechanisms and clinical aspects. Washington, DC: American Psychiatric Press.

    Google Scholar 

  • Yassa, R., Nastase, C., Dupont, D., & Thibeau, M. (1992). Tardive dyskinesia in elderly psychiatric patients: A 5-year study. American Journal of Psychiatry, 149, 1206–1211. doi:10.1176/ajp.149.9.1206.

    Article  PubMed  Google Scholar 

  • Yu, X. (2011, July 2). Three professors face sanctions following Harvard Medical School inquiry. The Harvard Crimson, p. 1.

    Google Scholar 

  • Zarrouf, F., & Bhanot, V. (2007). Neuroleptic malignant syndrome: Don’t let your guard down yet. Current Psychiatry, 6(8), 89–95.

    Google Scholar 

  • Zutshi, D., Cloud, L., Factor. S. (2014). Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: Experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov (N Y), 4, 266. Published online October 23, 2014. doi: 10.7916/D8MS3R8C. Retrieved May 29, 2016, from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219112/

Download references

Author information

Authors and Affiliations

  1. Private Practice, Ithaca, NY, USA

    Peter R. Breggin

Authors
  1. Peter R. Breggin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Life Sciences, University of Roehampton, London, United Kingdom

    James Davies

Rights and permissions

Reprints and permissions

Copyright information

© 2017 The Author(s)

About this chapter

Cite this chapter

Breggin, P.R. (2017). Neuroleptic (Antipsychotic) Drugs: An Epidemic of Tardive Dyskinesia and Related Brain Injuries Afflicting Tens of Millions. In: Davies, J. (eds) The Sedated Society. Palgrave Macmillan, Cham. https://doi.org/10.1007/978-3-319-44911-1_6

Download citation

Publish with us

Policies and ethics

Search

Navigation